Dosing and monitoring of methadone in pregnancy: Literature review

Canadian Journal of Hospital Pharmacy

Volumn 65, Issue 5, 2012, Pages 380-386

  Shiu, Jennifer R ^a   Ensom, Mary H H ^b,c  

^a ALBERTA HEALTH SERVICES   (Canada)

^b Faculty of Pharmaceutical Sciences   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Dosing; Methadone; Pharmacokinetics; Pregnancy

Indexed keywords

METHADONE;

CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FETUS HEART RATE; FIRST TRIMESTER PREGNANCY; HEART RATE VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHADONE TREATMENT; OPIATE ADDICTION; PLASMA PROTEIN BINDING; PREGNANCY; REVIEW; SKIN CONDUCTANCE; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME;

EID: 84876372302     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v65i5.1176     Document Type: Review

References (23)

1. Kaltenbach, K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-151. (Pubitemid 28141705)
2. Archie C. Methadone in the management of narcotic addiction in pregnancy. Curr Opin Obstet Gynecol 1998;10(6):435-440. (Pubitemid 29001322)
3. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol Series No. 43. Rockville (MD): Substance Abuse and Mental Health Service Administration (US); 2005 [cited 2012 Mar 20]. Available from: www.ncbi.nlm.nih.gov/books/NBK64164/
4. Effective medical treatment of opiate addiction. NIH consensus development conference statement November 17-19, 1997. Rockville (MD): National Institutes of Health; 1997 [cited 2011 Mar 20]. Available from: www.ncbi.nlm.nih.gov/books/NBK15146/
5. Uchtenhagen A, Ladjevic T, Rehm J. WHO guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. Geneva (Switzerland): World Health Organization; 2007 [cited 2011 Mar 20]. Available from: www.who.int/substance-abuse/activities/background-paper.pdf
6. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19(4):13-24.
7. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987;41(4):392-401. (Pubitemid 17058923)
8. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76(3):250-269. (Pubitemid 39221799)
9. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985;233(1):1-6. (Pubitemid 15083518)
10. Jarvis MAE, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999;18(4):51-61. (Pubitemid 30053427)
11. Wolff K, Boys A, Rostami-Hodjegan, Hay A, Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005;61(10):763-768. (Pubitemid 41674263)
12. Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, et al. Effect of pregnancy on gastrointestinal transit. Dig Dis Sci 1982;27(11):1015-1018. (Pubitemid 13233067)
13. Chilorio M, Darconza G, Piccioli E, De Carne M, Clemente C, Riezzo G. Gastric emptying and orocecal transit time in pregnancy. J Gastroenterol 2001;36(8):538-543. (Pubitemid 32791840)
14. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009;10(5):520-529.
15. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Philips EJ, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004;76(6):588-597. (Pubitemid 39601548)
16. Swift RM, Dudley M, DePetrillo P, Camara P, Griffiths W. Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1989;1(4):453-460.
17. Jansson LM, DiPietro JA, Velez M, Elko A, Knauer H, Kivlighan KT. Maternal methadone dosing schedule and fetal neurobehavior. J Matern Fetal Neonatal Med 2009;22(1):29-35.
18. DePetrillo PB, Rice JM. Methadone dosing and pregnancy: impact on program compliance. Int J Addict 1995;30(2):207-217.
19. Albright B, de la Torre L, Skipper B, Price S, Abbott P, Rayburn W. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011;41(4):347-353.
20. Wolff K, Sanderson M, Hay AWM, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 1991;37(2):205-209. (Pubitemid 21892628)
21. Torrens M, Castillo C, San L, del Moral E, González ML, de la Torre R. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend 1998;52(3):193-200. (Pubitemid 28529577)
22. Drozdick J 3rd, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002;187(5):1184-1188. (Pubitemid 35397455)
23. Barnes AJ, Brunet BR, Choo RE, Mura P, Johnson RE, Jones HE, et al. Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration. Ther Drug Monit 2010;32(4):497-503.